Lyotropic Delivery System
Lyotropic Delivery System (LDS Biotech) is a privately held Jerusalem-based nano-biotechnology company that licenses proprietary sub-100nm liquid-structured nano-domain drug delivery technology to pharmaceutical, nutraceutical, and cosmeceutical companies across oral, ophthalmic, topical, parenteral, nasal, and film routes.
- Company typePrivate
- Founded2013
- HeadquartersJerusalem, Israel
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lyotropic Delivery System does
Lyotropic Delivery System (LDS Biotech) is a privately held Israeli nano-biotechnology company founded in 2013 and headquartered at the Edmond J. Safra Campus in Jerusalem. The company develops a proprietary liquid-structured nano-domain drug delivery platform — self-assembled, sub-100nm liquid lipid-based domains that solubilize active pharmaceutical and nutraceutical ingredients at the interface, rather than in the core, enabling higher loading, enhanced bioavailability, and controlled or triggered release. The platform relies on FDA Inactive Ingredient Guideline (IIG)-approved excipients and is supported by a proprietary Monte Carlo Dynamic Simulation mathematical model that maps bioactive chemical structure to optimal excipient composition across parameters such as spontaneous curvature, interfacial elasticity, and micro-viscosity. Application modules span oral, ophthalmic, topical/transdermal, parenteral, nasal, and thin-film delivery routes.
LDS monetizes primarily through B2B technology licensing and out-licensing agreements with pharmaceutical, nutraceutical, and cosmeceutical companies, generating royalties on products sold globally under partner brand names and milestone payments from long-term collaborative development arrangements. Customer-facing commercial products already on market include curcumin, astaxanthin, lutein, beta-carotene, lycopene, CoQ10, omega fatty acids, vitamin D3, and phospholipid formulations. The clinical pipeline includes CBD-based products (Nantheia ATL5 series via Ananda Scientifics) being evaluated at multiple US academic medical centers across PTSD, opioid use disorder, chronic pain, social anxiety disorder, and smoking cessation indications, plus an ophthalmic cyclosporine product (Ocuvia / Operax) under an exclusive licensing option agreement via BioLight/OphRx. The company is led by founder Prof. Nissim Garti and holds 37+ granted patents globally with 40+ additional applications.
Lyotropic Delivery System firmographics
Firmographics- Name
- Lyotropic Delivery System
- Legal name
- LDS Biotech
- Website
- https://lds-biotech.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Lyotropic Delivery System (LDS Biotech) is a privately held Jerusalem-based nano-biotechnology company that licenses proprietary sub-100nm liquid-structured nano-domain drug delivery technology to pharmaceutical, nutraceutical, and cosmeceutical companies across oral, ophthalmic, topical, parenteral, nasal, and film routes.
- Ownership category
- akta.pro rank
Lyotropic Delivery System industry classification
Industry- Product category
- Drug Delivery Technology
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Lessors of Nonfinancial Intangible Assets (except Copyrighted Works) (533)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Miscellaneous Chemical Products (2890)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)
Keywords
Where Lyotropic Delivery System is headquartered
LocationHeadquarters
- HQ city
- Jerusalem
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
Lyotropic Delivery System business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure
Revenue model
- Technology Licensing: LDS generates revenue through licensing its proprietary drug delivery technology to pharmaceutical, nutraceutical, and cosmeceutical companies. The company out-licenses its technology for specific active molecules, indications, and routes of administration. Revenue includes royalties from products sold globally under different brand names.
- Collaborative Development: Partnership and license agreements with companies like Ananda Scientifics for oral delivery of cannabinoids. Long-term R&D agreements for future generations of products generate development fees and milestone payments.
- Nutraceutical Products: Cosmeceutical and nutraceutical products already being sold globally under different brand names, yielding royalties to LDS. Products include curcumin, astaxanthin, lutein, beta-carotene, lycopene, CoQ10, omega fatty acids, cannabinoids, vitamin D3, and phospholipids.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Lyotropic Delivery System product offering
Product offeringCore offering
LDS develops and out-licenses a proprietary liquid-structured nano-domain drug delivery platform that enhances the bioavailability, stability, and controlled release of insoluble and poorly permeable active molecules. It licenses this technology to pharmaceutical, nutraceutical, and cosmeceutical companies across oral, ocular, topical, parenteral, nasal, and film administration routes in exchange for royalties, milestones, and development fees.
Product overview
LDS is a biotech company offering a proprietary Lyotropic Delivery System technology platform—a unified drug delivery solution utilizing molecularly engineered liquid-structured nano-domains. The platform serves as the core technology underlying multiple product applications: oral delivery (Nantheia ATL5 for cannabinoids), ophthalmic delivery (Ocuvia), topical/transdermal delivery, parenteral injection (NEOPROL/NP09), nasal delivery for BBB crossing, and film-based sustained release. The technology enhances bioavailability of insoluble and poorly permeable molecules using FDA-IIG-approved excipients. The company also commercializes nutraceutical products including curcumin, astaxanthin, lutein, beta-carotene, lycopene, CoQ10, omega fatty acids, vitamin D3, and phosphatidylserine.
Differentiator
Problem solved
Functional benefit
Brands
- Ocuvia™: LDS-based ophthalmic drug delivery technology presented at the 43rd Annual J.P. Morgan Healthcare Conference in January 2025.
Products and services
- LDS Lyotropic Delivery System Technology Platform Proprietary drug delivery platform using liquid-structured nano-domains (<100nm) that enhances bioavailability and efficacy of insoluble and poorly permeable active molecules using FDA-IIG-approved excipients. Tailored for pharmaceutical, nutraceutical, and cosmeceutical companies across multiple administration routes.
- Oral Delivery System Delivery technology that embeds generic or innovative bio-actives (APIs) to achieve enhanced bioavailability for oral uptake, protecting active molecules from harsh GI tract conditions. For pharmaceutical and nutraceutical companies.
- Ophthalmic Delivery System Nano-sized domain delivery vehicles providing extensive interfacial contact with the eye epithelium, enabling enhanced permeation to anterior and posterior eye segments for water-insoluble molecules. For pharmaceutical companies developing ocular therapeutics.
- Topical and Transdermal Delivery System Topical delivery systems with nano-liquid structures in soft gels or thin films enabling transport of insoluble active molecules to skin layers (epidermis/dermis) and nails, for skin disease treatment and transdermal absorption. For cosmeceutical and pharmaceutical companies.
- Parenteral Delivery System Injectable formulations using nano-domains to encapsulate APIs, providing thermodynamic stability, reduced injection pain, improved solubility, decreased microbial contamination, and enhanced bioavailability. For pharmaceutical companies.
- Nasal Delivery System Formulations designed for nasal applications for drug compounds that must cross the blood-brain barrier to reach the brain, enabling fast, quantitative, and accurate dosing. For pharmaceutical companies targeting CNS conditions.
- Film Delivery Technology Multi-layer, self-adhesive, thin, transparent film technology that embeds nano-domains loaded with active molecules, providing sustained release for chronic disease treatments on nails, joints, and skin. For pharmaceutical and cosmeceutical companies.
- Nantheia ATL5 LDS-based oral CBD product developed in partnership with Ananda Scientific, featuring soft-gels, instant powders, and dilutable liquids for cannabinoid delivery; used in multiple clinical trials for OUD, PTSD, chronic pain, and anxiety indications.
- Ocuvia Ophthalmic Product Novel LDS-based ophthalmic drug delivery product (including cyclosporine formulation). Presented at the J.P. Morgan Healthcare Conference and subject of an exclusive licensing option agreement with a leading pharmaceutical company.
- NEOPROL Formulation (NP09) Parenteral (injectable) formulation demonstrating bio-equivalence to commercial products, validated in PK studies in dogs. For pharmaceutical companies.
Quantifiable outcome
- Phase 1A clinical trial for oral CBD uptake completed in 2020 demonstrating very fast CBD absorption (Tmax) and very high content of CBD active ingredient into the bloodstream
- +3 more outcomes
Companies that use Lyotropic Delivery System
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
Lyotropic Delivery System technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Lyotropic Delivery System partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- UCLA David Geffen School of MedicinecoreClinical trial collaboration for smoking cessation using Nantheia ATL5 with LDS Liquid Structure CBD delivery technology. UCLA announced commencement of clinical trial evaluating LDS-based CBD formulation for smoking cessation.
- Yale School of MedicinecoreFDA-approved clinical trial for Nantheia ATL5 for opioid use disorder and chronic pain treatment using LDS Liquid Structure delivery technology. Yale is conducting clinical evaluation of LDS-based CBD delivery for these indications.
- Golden Heart Flower (GHF)minorGHF showcased LDS novel delivery technology at the Adult Poly-Body Disease (APBD) Scientific & Community Conference for orphan indication treatment. GHF is developing treatments for orphan diseases using LDS technology.
- BioLight Life Sciences / OphRxcoreBioLight subsidiary OphRx signed exclusive option for license agreement with leading pharmaceutical company for novel LDS-based ophthalmic technology. Positive clinical trial results achieved for cyclosporine ophthalmic formulation using LDS technology. Biolight operates in the Israeli market.
- NYU Grossman School of MedicinecoreMultiple clinical trial collaborations including first patient enrolled for Social Anxiety Disorder (SAD) treatment, PTSD trials, and opioid-sparing treatment in participants with radiculopathic pain using LDS Liquid Structure CBD delivery technology.
- University of Nebraska Medical CentercoreFDA approval of IND for clinical trial exploring PTSD treatment using LDS Liquid Structure CBD delivery technology. First patient enrolled March 2023.
- Mount Sinai Icahn School of MedicinecoreClinical evaluation of Liquid Structure CBD for opioid use disorder (OUD) using LDS Liquid Structure delivery technology.
- Ananda ScientificscoreLDS entered into a partnership and license agreement with Ananda Scientifics (US-based company) for oral delivery of cannabinoids. Ananda Scientifics has signed a long-term R&D agreement with LDS for future generations of oral cannabinoid-based products in soft-gels, instant powders, and dilutable liquids. Technology is protected by patents issued in several countries and nutraceutical products are currently sold globally under different brand names yielding royalties to LDS. Multiple clinical trials ongoing including Phase 1A (completed 2020) and Phase 2a.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
Lyotropic Delivery System competitors and assessment
Company assessmentOthers
Broad incumbents
- CordenPharma: Global CDMO offering API, peptide, and lipid-based drug product development including nano-formulations. Comparable as a contract manufacturer with overlapping lipid/delivery capabilities for pharma and nutraceutical customers.
- Croda International: Global specialty chemicals and excipient company serving pharmaceutical and personal care with drug delivery-enabling ingredients. Comparable as a much larger, established supplier of delivery-system components with broad portfolio reach.
- Evonik Industries: German specialty chemicals and CDMO with pharmaceutical delivery solutions including lipid-based and polymeric systems. Comparable as a large, diversified player with overlapping lipid and nano-delivery capabilities.
- Ligand Pharmaceuticals: US biopharmaceutical company that monetizes proprietary drug delivery and formulation platforms (e.g., Captisol) primarily through licensing and royalty agreements. Comparable platform-licensing business model applied to formulation technology.
- BioNTech: German biotechnology company that pioneered lipid nanoparticle delivery for mRNA vaccines and therapeutics. Comparable for its foundational LNP delivery IP and licensing partnerships, though at vastly larger scale and focused on nucleic acid payloads.
Direct peers
- Lipocine: US clinical-stage biopharmaceutical company focused on oral delivery of poorly soluble drugs using lipid-based technology. Directly comparable as a small lipid-delivery platform company commercializing through licensing and partnership arrangements.
- Acuitas Therapeutics: Canadian lipid nanoparticle (LNP) delivery technology company that develops delivery systems for nucleic acid and small-molecule therapeutics. Most directly comparable to LDS in lipid-based nano-delivery platform technology and out-licensing business model.
- NanoCarrier: Japanese clinical-stage biotech developing micellar and polymeric nanoparticle drug delivery systems for oncology and other indications. Comparable as a smaller specialty nano-delivery platform targeting pharma partnership and licensing economics.
Emerging players
- Arcturus Therapeutics: US clinical-stage mRNA medicines company that developed its own lipid nanoparticle delivery platform (LUNAR) for nucleic acid therapeutics. Comparable as a smaller platform company with proprietary lipid-based delivery technology targeting licensing and partnership models.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Lyotropic Delivery System social profiles
Digital presenceLyotropic Delivery System compliance and trust
Trust signalCompliance1 record
Lyotropic Delivery System financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lyotropic Delivery System leadership team
Management profileNumber of profiles
Profiles1 record
Lyotropic Delivery System subsidiaries and ownership
Company hierarchySubsidiaries1 record
Lyotropic Delivery System funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lyotropic Delivery System M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lyotropic Delivery System
What does Lyotropic Delivery System do?
LDS develops and out-licenses a proprietary liquid-structured nano-domain drug delivery platform that enhances the bioavailability, stability, and controlled release of insoluble and poorly permeable active molecules. It licenses this technology to pharmaceutical, nutraceutical, and cosmeceutical companies across oral, ocular, topical, parenteral, nasal, and film administration routes in exchange for royalties, milestones, and development fees.
Is Lyotropic Delivery System a public or private company?
Lyotropic Delivery System is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Lyotropic Delivery System founded?
Lyotropic Delivery System was founded in 2013. It employs 1 to 10 people.
Where is Lyotropic Delivery System based?
Lyotropic Delivery System is headquartered in Jerusalem, Israel, in the Middle East region.
How does Lyotropic Delivery System make money?
Three revenue lines are on record. Technology Licensing is the primary driver. The others are collaborative Development and nutraceutical Products.
Who are Lyotropic Delivery System's main competitors?
Catalent is listed as an others. Broad incumbents are CordenPharma, Croda International, Evonik Industries, Ligand Pharmaceuticals and BioNTech. Direct peers are Lipocine, Acuitas Therapeutics and NanoCarrier. Arcturus Therapeutics is listed as an emerging player.
Does Lyotropic Delivery System have an API?
No public API is recorded for Lyotropic Delivery System.
What industry is Lyotropic Delivery System in?
Lyotropic Delivery System's product category is Drug Delivery Technology. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 32541 and its SIC code is 2834.